Leronlimab mentioned in this recent publication on
Post# of 148112
"An excellent safety profile was also determined for the monoclonal antibody PRO140 (Leronlimab) [243]. Remarkably, this antibody has the potential to provide HIV-1-prophylaxis after a single subcutaneous injection a week and is currently further under investigation in a phase IIb and phase III study."
https://www.mdpi.com/2076-2607/9/2/228
https://www.mdpi.com/2076-2607/9/2/228/pdf